Report of Foreign Issuer (6-k)
February 23 2017 - 11:33AM
Edgar (US Regulatory)
FORM
6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For
period ending
23 February
2017
GlaxoSmithKline
plc
(Name
of registrant)
980
Great West Road, Brentford, Middlesex, TW8 9GS
(Address of
principal executive offices)
Indicate by check
mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate by check
mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange
Act of 1934.
Yes
No x
GlaxoSmithKline plc
(the '
Company
')
Transaction
notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dr M M Slaoui
|
b)
|
Position/status
|
Chairman, Global Vaccines
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the
financial
instrument
|
GlaxoSmithKline plc American Depositary Shares
('ADSs')
ISIN:
US37733W1053
|
b)
|
Nature
of
the
transaction
|
An increase of 53 ADSs following the notional allocation of ADSs on
22 February 2017, at a price of $41.03 per ADS, as a result of the
revaluation of the cash element of the notional investment held
within the GSK 401(K) plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
$
41.03
|
53
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
n/a (single transaction)
|
e)
|
Date of
the
transaction
|
2017-02-22
|
f)
|
Place
of
the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dr K Slaoui
|
b)
|
Position/status
|
PCA of Dr M M Slaoui (Chairman, Global Vaccines)
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the
financial
instrument
|
GlaxoSmithKline plc American Depositary Shares
('ADSs')
ISIN:
US37733W1053
|
b)
|
Nature
of
the
transaction
|
An increase of 13 ADSs following the notional allocation of ADSs on
22 February 2017, at a price of $41.03 per ADS, as a result of the
revaluation of the cash element of the notional investment held
within the GSK 401(K) plan.
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
$41.03
|
13
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
n/a (single transaction)
|
e)
|
Date of
the
transaction
|
2017-02-22
|
f)
|
Place
of
the
transaction
|
n/a
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: February
23, 2017
|
|
|
|
|
By: VICTORIA
WHYTE
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024